Most Read Articles
15 Mar 2019
Roche recently announced their targeted therapy combination pertuzumab (Perjeta®)-trastuzumab (Herceptin®) plus conventional chemotherapy for treatment of early breast cancer in those with a subtype known as HER2-positive. The combination was previously used in the metastatic breast cancer setting, where cancer had already spread. There, it was able to prolong cancer sufferers’ lives significantly. Because of its effectiveness, the two-drug combo is new available for treatment of early HER2-positive breast cancer to further reduce the risk of metastasis or cancer recurrence. HER2-positive breast cancers usually spread faster and affect younger women and make up about one quarter of all newly diagnosed breast cancers. 

Older age, IBD duration as risk factors for colitis-associated neoplasia

11 Jan 2019

Among patients with inflammatory bowel disease (IBD), older age at the time of IBD diagnosis and longer disease duration are associated with a heightened risk of developing colitis-associated neoplasia, a study has found.

Researchers looked at 29 adult IBD patients who developed CAN, of whom 69.0 percent had ulcerative colitis and 31.0 percent had Crohn’s disease, and 87 non-CAN controls. They matched the two patient groups according to gender and IBD type. 

In the CAN group, eight patients (27.6 percent) had colorectal cancer (CRC), 20 (69.0 percent) had low-grade dysplasia and one (3.4 percent) had high-grade dysplasia. Compared with controls, CAN patients were older at the time of IBD diagnosis (49.9 vs 36.9 years; p<0.001) and had longer duration of IBD (3.4 vs 2.1 years; p=0.35).

Multivariate logistic regression analysis confirmed that the development of CAN was significantly associated with older age at the time of IBD diagnosis (odds ratio [OR], 1.09; 95 percent CI, 1.04–1.14; p<0.001) and longer IBD disease duration (OR, 1.14; 1.03–1.27; p=0.013).

The observed associations were more pronounced in IBD patients with CRC (age at diagnosis, p=0.012; disease duration, p=0.019) than in those with dysplasia.

These results should be interpreted in light of potential limitations, particularly the retrospective study design, researchers noted. Nevertheless, the data may serve as a springboard for developing a risk-prediction model, which can be applied in daily clinical practice for an individualized approach to CAN surveillance in IBD patients.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
15 Mar 2019
Roche recently announced their targeted therapy combination pertuzumab (Perjeta®)-trastuzumab (Herceptin®) plus conventional chemotherapy for treatment of early breast cancer in those with a subtype known as HER2-positive. The combination was previously used in the metastatic breast cancer setting, where cancer had already spread. There, it was able to prolong cancer sufferers’ lives significantly. Because of its effectiveness, the two-drug combo is new available for treatment of early HER2-positive breast cancer to further reduce the risk of metastasis or cancer recurrence. HER2-positive breast cancers usually spread faster and affect younger women and make up about one quarter of all newly diagnosed breast cancers.